WP. Kuala Lumpur, Federal Territory of Kuala Lumpur, Malaysia
Passionate and motivated pharmacy graduate currently serving as a medical representative in the pharma line in hope of bringing the best treatments to as many patients as possible.
Immunotherapy portfolio with a focus on Lung & GI indications. Year 2026 Q1 (GI focused + Lung vacancy coverage) - SvT 108% with +52.8% growth - Rm 691,875 sales increment - 28 new IO pts initiation - 10 new prescribers - Achieved >100% SvT for both individual territory & vacancy coverage Dual-IO breakthrough - Achieved first-ever dual-IO combination initiations in both MOH & MOE sectors in East Coast states. - Developed 10 new dual-IO prescribers with 16 patient initiations Year 2025 Q4 2025 (Immuno , GI+Lung) - SvT 100% with +31% growth - 35 new pt initiations YTD (Q2-Q4) - 15 new oncologist prescribers 2025 YTD SvT 104% with +35% growth
Consistent achievement of sales target with positive triple digit growth. - Q1 108% individual SvT with 177% growth and total 9 new accounts opening - Q2 119% individual SvT with 150% growth and 9 new accounts opening - Q3 118% individual SvT with 126% growth with 11 new accounts opening - Q4 104% individual SvT with 114% growth and 6 new accounts opening - 2022 Overall YTD 112% sales achievement with 114% growth - Successfully regained 100% lost accounts - 2 Year Achiever Consistency Award
Pharmaceutical Industry Placement
Portfolio includes targeted therapy, hormonal therapy and immunotherapy Year 2025 Q1 (Targeted + Hormonal) - SvT 127% with +39.5% growth - RM 558,660 increase in sales value (Q1'25 vs Q1'24) Q2 (Immunotherapy , TA change) - SvT 92% with +27% growth Q3 (Immuno , GI+Lung) - SvT 96% with +43% growth - YTD patient initiation grew by +143% - 20 additional pt initiations (Q3'25 vs Q3'24) - 12 new oncologist prescribers > Q2 People Recognition award > Q4 Best Practice sharing > 2025 POA taskforce co-lead Year 2024 (Targeted + Hormonal) - Q1 SvT 116% with +6.1% growth - Q2 SvT 81% with -27.2% growth (Gov tender impact) - Q3 SvT 155% with +59.9% growth - Q4 SvT 93% with +60.4% growth - FY 110% SvT achievement with +21.6% YTD growth - FY RM 1,072,827 increase in sales value (FY'24 vs FY'23) - Highest achievement award (Oncology unit, Q3) - H2 booster award (Top team organisation-wide) - Best practice award (Year 2024, Franchise-wide)
Medication dispensing with consultation across different TAs
- Sandoz division , Novartis (May onwards) - TA coverage includes Rheumatology, Respiratory, Gastroenterology, Hepatology and Neurology - 75 new accounts opening - YTD Growth of 7% - Average RR Growth of 12% (May onwards vs 2022) - 15 RLMs conducted across Clinic, Hospital & Pharmacy channels - 1 virtual RTD conducted (roughly 130 participants)
A history of covering CVRM pipelines with the current main focus on Diabetes treatment option (SGLT2i family). Equipped with extensive medical knowledge of the targeted therapeutic area, patient-centric selling skills along with polished business analytical & planning skills. Consistent achievement of sales target with positive double to triple digit growth. Actively participated in cross-functional collaboration such as program roll-out, marketing material task force as well as event emceeing. At team level, I actively participated in the leading of selling skill trainings, medical paper presentation as well as being a mentor for new joiners. 2021 Sales Performance (New Territory) - Q1 started out with -8% growth - Q2 Top Team Award with 38% individual growth - Q3 Top Team Award with 146% individual SvT w/ 49.57% growth - Q4 Top Individual Award with 170% individual SvT w/ 118% growth - 2021 Overall YTD 117% SvT achievement with 56% growth - Regained 11/12 lost accounts (91%) - Opened 34 new accounts - Q4 Highest Achiever MR - Best Practice MR 2021 2020 Sales Performance (Crestor + DAPA) - Turned heavy degrowth into positive 16% growth by end of the year - Positive 50% and 28% quarter-to-quarter growth for Q2-Q3 and Q3-Q4 respectively. - Opened a total of 17 new accounts - Conducted 37 virtual scientific sharing (VEM) with HCPs in Q4 - Conducted 7 RLMs and 1 physical RTD event between pandemic lockdown